Research Methodology

The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:

★Stage 1 SECONDARY RESEARCH

The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.

★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES

After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.

★Stage 3 ANALYSIS OF THE GATHERED DATA

The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.

★Stage 4 QUANTITATIVE DATA

The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.

★Stage 5 QUALITY CONTROL

Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Beta-emitting
1.2.3 Targeted Alpha Therapy
1.3 Market by Application
1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
1.3.2 Solid Tumor
1.3.3 Non Hodgkin Lymphoma
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radioimmunotherapy Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Radioimmunotherapy Revenue Market Share by Region (2020-2025)
2.4 Global Radioimmunotherapy Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Radioimmunotherapy Market Size and Prospective (2020-2031)
2.5.2 Europe Radioimmunotherapy Market Size and Prospective (2020-2031)
2.5.3 China Radioimmunotherapy Market Size and Prospective (2020-2031)
2.5.4 Latin America Radioimmunotherapy Market Size and Prospective (2020-2031)
2.5.5 Middle East & Africa Radioimmunotherapy Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Radioimmunotherapy Historic Market Size by Type (2020-2025)
3.2 Global Radioimmunotherapy Forecasted Market Size by Type (2026-2031)
3.3 Different Types Radioimmunotherapy Representative Players
4 Breakdown Data by Application
4.1 Global Radioimmunotherapy Historic Market Size by Application (2020-2025)
4.2 Global Radioimmunotherapy Forecasted Market Size by Application (2026-2031)
4.3 New Sources of Growth in Radioimmunotherapy Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Radioimmunotherapy Players by Revenue (2020-2025)
5.1.2 Global Radioimmunotherapy Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Radioimmunotherapy Revenue
5.4 Global Radioimmunotherapy Market Concentration Analysis
5.4.1 Global Radioimmunotherapy Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Radioimmunotherapy Revenue in 2024
5.5 Global Key Players of Radioimmunotherapy Head office and Area Served
5.6 Global Key Players of Radioimmunotherapy, Product and Application
5.7 Global Key Players of Radioimmunotherapy, Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Radioimmunotherapy Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Radioimmunotherapy Market Size by Type (2020-2025)
6.1.2.2 North America Radioimmunotherapy Market Share by Type (2020-2025)
6.1.3 North America Market Size by Application
6.1.3.1 North America Radioimmunotherapy Market Size by Application (2020-2025)
6.1.3.2 North America Radioimmunotherapy Market Share by Application (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Radioimmunotherapy Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Radioimmunotherapy Market Size by Type (2020-2025)
6.2.2.2 Europe Radioimmunotherapy Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe Radioimmunotherapy Market Size by Application (2020-2025)
6.2.3.2 Europe Radioimmunotherapy Market Share by Application (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 China Market: Players, Segments and Downstream
6.3.1 China Radioimmunotherapy Revenue by Company (2020-2025)
6.3.2 China Market Size by Type
6.3.2.1 China Radioimmunotherapy Market Size by Type (2020-2025)
6.3.2.2 China Radioimmunotherapy Market Share by Type (2020-2025)
6.3.3 China Market Size by Application
6.3.3.1 China Radioimmunotherapy Market Size by Application (2020-2025)
6.3.3.2 China Radioimmunotherapy Market Share by Application (2020-2025)
6.3.4 China Market Trend and Opportunities
6.4 Latin America Market: Players, Segments and Downstream
6.4.1 Latin America Radioimmunotherapy Revenue by Company (2020-2025)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America Radioimmunotherapy Market Size by Type (2020-2025)
6.4.2.2 Latin America Radioimmunotherapy Market Share by Type (2020-2025)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America Radioimmunotherapy Market Size by Application (2020-2025)
6.4.3.2 Latin America Radioimmunotherapy Market Share by Application (2020-2025)
6.4.4 Latin America Market Trend and Opportunities
6.5 Middle East & Africa Market: Players, Segments and Downstream
6.5.1 Middle East & Africa Radioimmunotherapy Revenue by Company (2020-2025)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa Radioimmunotherapy Market Size by Type (2020-2025)
6.5.2.2 Middle East & Africa Radioimmunotherapy Market Share by Type (2020-2025)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa Radioimmunotherapy Market Size by Application (2020-2025)
6.5.3.2 Middle East & Africa Radioimmunotherapy Market Share by Application (2020-2025)
6.5.4 Middle East & Africa Market Trend and Opportunities
7 Key Players Profiles
7.1 Bayer
7.1.1 Bayer Company Details
7.1.2 Bayer Business Overview
7.1.3 Bayer Radioimmunotherapy Introduction
7.1.4 Bayer Revenue in Radioimmunotherapy Business (2020-2025)
7.1.5 Bayer Recent Development
7.2 Novartis
7.2.1 Novartis Company Details
7.2.2 Novartis Business Overview
7.2.3 Novartis Radioimmunotherapy Introduction
7.2.4 Novartis Revenue in Radioimmunotherapy Business (2020-2025)
7.2.5 Novartis Recent Development
7.3 Lantheus
7.3.1 Lantheus Company Details
7.3.2 Lantheus Business Overview
7.3.3 Lantheus Radioimmunotherapy Introduction
7.3.4 Lantheus Revenue in Radioimmunotherapy Business (2020-2025)
7.3.5 Lantheus Recent Development
7.4 Aurobindo Pharma
7.4.1 Aurobindo Pharma Company Details
7.4.2 Aurobindo Pharma Business Overview
7.4.3 Aurobindo Pharma Radioimmunotherapy Introduction
7.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2020-2025)
7.4.5 Aurobindo Pharma Recent Development
7.5 Mundipharma
7.5.1 Mundipharma Company Details
7.5.2 Mundipharma Business Overview
7.5.3 Mundipharma Radioimmunotherapy Introduction
7.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2020-2025)
7.5.5 Mundipharma Recent Development
7.6 China Isotope & Radiation
7.6.1 China Isotope & Radiation Company Details
7.6.2 China Isotope & Radiation Business Overview
7.6.3 China Isotope & Radiation Radioimmunotherapy Introduction
7.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2020-2025)
7.6.5 China Isotope & Radiation Recent Development
7.7 Curium Pharmaceuticals
7.7.1 Curium Pharmaceuticals Company Details
7.7.2 Curium Pharmaceuticals Business Overview
7.7.3 Curium Pharmaceuticals Radioimmunotherapy Introduction
7.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2020-2025)
7.7.5 Curium Pharmaceuticals Recent Development
7.8 Gilead Sciences
7.8.1 Gilead Sciences Company Details
7.8.2 Gilead Sciences Business Overview
7.8.3 Gilead Sciences Radioimmunotherapy Introduction
7.8.4 Gilead Sciences Revenue in Radioimmunotherapy Business (2020-2025)
7.8.5 Gilead Sciences Recent Development
7.9 Clarity Pharmaceuticals
7.9.1 Clarity Pharmaceuticals Company Details
7.9.2 Clarity Pharmaceuticals Business Overview
7.9.3 Clarity Pharmaceuticals Radioimmunotherapy Introduction
7.9.4 Clarity Pharmaceuticals Revenue in Radioimmunotherapy Business (2020-2025)
7.9.5 Clarity Pharmaceuticals Recent Development
7.10 Curasight
7.10.1 Curasight Company Details
7.10.2 Curasight Business Overview
7.10.3 Curasight Radioimmunotherapy Introduction
7.10.4 Curasight Revenue in Radioimmunotherapy Business (2020-2025)
7.10.5 Curasight Recent Development
7.11 Nordic Nanovector
7.11.1 Nordic Nanovector Company Details
7.11.2 Nordic Nanovector Business Overview
7.11.3 Nordic Nanovector Radioimmunotherapy Introduction
7.11.4 Nordic Nanovector Revenue in Radioimmunotherapy Business (2020-2025)
7.11.5 Nordic Nanovector Recent Development
7.12 Philogen
7.12.1 Philogen Company Details
7.12.2 Philogen Business Overview
7.12.3 Philogen Radioimmunotherapy Introduction
7.12.4 Philogen Revenue in Radioimmunotherapy Business (2020-2025)
7.12.5 Philogen Recent Development
7.13 RadioMedix
7.13.1 RadioMedix Company Details
7.13.2 RadioMedix Business Overview
7.13.3 RadioMedix Radioimmunotherapy Introduction
7.13.4 RadioMedix Revenue in Radioimmunotherapy Business (2020-2025)
7.13.5 RadioMedix Recent Development
7.14 Telix Pharmaceuticals
7.14.1 Telix Pharmaceuticals Company Details
7.14.2 Telix Pharmaceuticals Business Overview
7.14.3 Telix Pharmaceuticals Radioimmunotherapy Introduction
7.14.4 Telix Pharmaceuticals Revenue in Radioimmunotherapy Business (2020-2025)
7.14.5 Telix Pharmaceuticals Recent Development
7.15 Orano Med
7.15.1 Orano Med Company Details
7.15.2 Orano Med Business Overview
7.15.3 Orano Med Radioimmunotherapy Introduction
7.15.4 Orano Med Revenue in Radioimmunotherapy Business (2020-2025)
7.15.5 Orano Med Recent Development
7.16 Actinium Pharmaceuticals
7.16.1 Actinium Pharmaceuticals Company Details
7.16.2 Actinium Pharmaceuticals Business Overview
7.16.3 Actinium Pharmaceuticals Radioimmunotherapy Introduction
7.16.4 Actinium Pharmaceuticals Revenue in Radioimmunotherapy Business (2020-2025)
7.16.5 Actinium Pharmaceuticals Recent Development
7.17 Y-mAbs Therapeutics
7.17.1 Y-mAbs Therapeutics Company Details
7.17.2 Y-mAbs Therapeutics Business Overview
7.17.3 Y-mAbs Therapeutics Radioimmunotherapy Introduction
7.17.4 Y-mAbs Therapeutics Revenue in Radioimmunotherapy Business (2020-2025)
7.17.5 Y-mAbs Therapeutics Recent Development
7.18 Fusion Pharmaceuticals
7.18.1 Fusion Pharmaceuticals Company Details
7.18.2 Fusion Pharmaceuticals Business Overview
7.18.3 Fusion Pharmaceuticals Radioimmunotherapy Introduction
7.18.4 Fusion Pharmaceuticals Revenue in Radioimmunotherapy Business (2020-2025)
7.18.5 Fusion Pharmaceuticals Recent Development
8 Radioimmunotherapy Market Dynamics
8.1 Radioimmunotherapy Industry Trends
8.2 Radioimmunotherapy Market Drivers
8.3 Radioimmunotherapy Market Challenges
8.4 Radioimmunotherapy Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

List of Tables
Table 1. Global Radioimmunotherapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Radioimmunotherapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Market Radioimmunotherapy Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
Table 4. Global Radioimmunotherapy Revenue (US$ Million) Market Share by Region (2020-2025)
Table 5. Global Radioimmunotherapy Revenue Share by Region (2020-2025)
Table 6. Global Radioimmunotherapy Revenue (US$ Million) Forecast by Region (2026-2031)
Table 7. Global Radioimmunotherapy Revenue Share Forecast by Region (2026-2031)
Table 8. Global Radioimmunotherapy Market Size by Type (2020-2025) & (US$ Million)
Table 9. Global Radioimmunotherapy Revenue Market Share by Type (2020-2025)
Table 10. Global Radioimmunotherapy Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 11. Global Radioimmunotherapy Revenue Market Share by Type (2026-2031)
Table 12. Representative Players of Each Type
Table 13. Global Radioimmunotherapy Market Size by Application (2020-2025) & (US$ Million)
Table 14. Global Radioimmunotherapy Revenue Market Share by Application (2020-2025)
Table 15. Global Radioimmunotherapy Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 16. Global Radioimmunotherapy Revenue Market Share by Application (2026-2031)
Table 17. New Sources of Growth in Radioimmunotherapy Application
Table 18. Global Radioimmunotherapy Revenue by Players (2020-2025) & (US$ Million)
Table 19. Global Radioimmunotherapy Market Share by Players (2020-2025)
Table 20. Global Top Radioimmunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioimmunotherapy as of 2024)
Table 21. Ranking of Global Top Radioimmunotherapy Companies by Revenue (US$ Million) in 2024
Table 22. Global 5 Largest Players Market Share by Radioimmunotherapy Revenue (CR5 and HHI) & (2020-2025)
Table 23. Global Key Players of Radioimmunotherapy, Headquarters and Area Served
Table 24. Global Key Players of Radioimmunotherapy, Product and Application
Table 25. Global Key Players of Radioimmunotherapy, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America Radioimmunotherapy Revenue by Company (2020-2025) & (US$ Million)
Table 28. North America Radioimmunotherapy Revenue Market Share by Company (2020-2025)
Table 29. North America Radioimmunotherapy Market Size by Type (2020-2025) & (US$ Million)
Table 30. North America Radioimmunotherapy Market Size by Application (2020-2025) & (US$ Million)
Table 31. Europe Radioimmunotherapy Revenue by Company (2020-2025) & (US$ Million)
Table 32. Europe Radioimmunotherapy Revenue Market Share by Company (2020-2025)
Table 33. Europe Radioimmunotherapy Market Size by Type (2020-2025) & (US$ Million)
Table 34. Europe Radioimmunotherapy Market Size by Application (2020-2025) & (US$ Million)
Table 35. China Radioimmunotherapy Revenue by Company (2020-2025) & (US$ Million)
Table 36. China Radioimmunotherapy Revenue Market Share by Company (2020-2025)
Table 37. China Radioimmunotherapy Market Size by Type (2020-2025) & (US$ Million)
Table 38. China Radioimmunotherapy Market Size by Application (2020-2025) & (US$ Million)
Table 39. Latin America Radioimmunotherapy Revenue by Company (2020-2025) & (US$ Million)
Table 40. Latin America Radioimmunotherapy Revenue Market Share by Company (2020-2025)
Table 41. Latin America Radioimmunotherapy Market Size by Type (2020-2025) & (US$ Million)
Table 42. Latin America Radioimmunotherapy Market Size by Application (2020-2025) & (US$ Million)
Table 43. Middle East & Africa Radioimmunotherapy Revenue by Company (2020-2025) & (US$ Million)
Table 44. Middle East & Africa Radioimmunotherapy Revenue Market Share by Company (2020-2025)
Table 45. Middle East & Africa Radioimmunotherapy Market Size by Type (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Radioimmunotherapy Market Size by Application (2020-2025) & (US$ Million)
Table 47. Bayer Company Details
Table 48. Bayer Business Overview
Table 49. Bayer Radioimmunotherapy Product
Table 50. Bayer Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 51. Bayer Recent Development
Table 52. Novartis Company Details
Table 53. Novartis Business Overview
Table 54. Novartis Radioimmunotherapy Product
Table 55. Novartis Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 56. Novartis Recent Development
Table 57. Lantheus Company Details
Table 58. Lantheus Business Overview
Table 59. Lantheus Radioimmunotherapy Product
Table 60. Lantheus Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 61. Lantheus Recent Development
Table 62. Aurobindo Pharma Company Details
Table 63. Aurobindo Pharma Business Overview
Table 64. Aurobindo Pharma Radioimmunotherapy Product
Table 65. Aurobindo Pharma Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 66. Aurobindo Pharma Recent Development
Table 67. Mundipharma Company Details
Table 68. Mundipharma Business Overview
Table 69. Mundipharma Radioimmunotherapy Product
Table 70. Mundipharma Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 71. Mundipharma Recent Development
Table 72. China Isotope & Radiation Company Details
Table 73. China Isotope & Radiation Business Overview
Table 74. China Isotope & Radiation Radioimmunotherapy Product
Table 75. China Isotope & Radiation Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 76. China Isotope & Radiation Recent Development
Table 77. Curium Pharmaceuticals Company Details
Table 78. Curium Pharmaceuticals Business Overview
Table 79. Curium Pharmaceuticals Radioimmunotherapy Product
Table 80. Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 81. Curium Pharmaceuticals Recent Development
Table 82. Gilead Sciences Company Details
Table 83. Gilead Sciences Business Overview
Table 84. Gilead Sciences Radioimmunotherapy Product
Table 85. Gilead Sciences Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 86. Gilead Sciences Recent Development
Table 87. Clarity Pharmaceuticals Company Details
Table 88. Clarity Pharmaceuticals Business Overview
Table 89. Clarity Pharmaceuticals Radioimmunotherapy Product
Table 90. Clarity Pharmaceuticals Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 91. Clarity Pharmaceuticals Recent Development
Table 92. Curasight Company Details
Table 93. Curasight Business Overview
Table 94. Curasight Radioimmunotherapy Product
Table 95. Curasight Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 96. Curasight Recent Development
Table 97. Nordic Nanovector Company Details
Table 98. Nordic Nanovector Business Overview
Table 99. Nordic Nanovector Radioimmunotherapy Product
Table 100. Nordic Nanovector Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 101. Nordic Nanovector Recent Development
Table 102. Philogen Company Details
Table 103. Philogen Business Overview
Table 104. Philogen Radioimmunotherapy Product
Table 105. Philogen Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 106. Philogen Recent Development
Table 107. RadioMedix Company Details
Table 108. RadioMedix Business Overview
Table 109. RadioMedix Radioimmunotherapy Product
Table 110. RadioMedix Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 111. RadioMedix Recent Development
Table 112. Telix Pharmaceuticals Company Details
Table 113. Telix Pharmaceuticals Business Overview
Table 114. Telix Pharmaceuticals Radioimmunotherapy Product
Table 115. Telix Pharmaceuticals Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 116. Telix Pharmaceuticals Recent Development
Table 117. Orano Med Company Details
Table 118. Orano Med Business Overview
Table 119. Orano Med Radioimmunotherapy Product
Table 120. Orano Med Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 121. Orano Med Recent Development
Table 122. Actinium Pharmaceuticals Company Details
Table 123. Actinium Pharmaceuticals Business Overview
Table 124. Actinium Pharmaceuticals Radioimmunotherapy Product
Table 125. Actinium Pharmaceuticals Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 126. Actinium Pharmaceuticals Recent Development
Table 127. Y-mAbs Therapeutics Company Details
Table 128. Y-mAbs Therapeutics Business Overview
Table 129. Y-mAbs Therapeutics Radioimmunotherapy Product
Table 130. Y-mAbs Therapeutics Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 131. Y-mAbs Therapeutics Recent Development
Table 132. Fusion Pharmaceuticals Company Details
Table 133. Fusion Pharmaceuticals Business Overview
Table 134. Fusion Pharmaceuticals Radioimmunotherapy Product
Table 135. Fusion Pharmaceuticals Revenue in Radioimmunotherapy Business (2020-2025) & (US$ Million)
Table 136. Fusion Pharmaceuticals Recent Development
Table 137. Radioimmunotherapy Market Trends
Table 138. Radioimmunotherapy Market Drivers
Table 139. Radioimmunotherapy Market Challenges
Table 140. Radioimmunotherapy Market Restraints
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources


List of Figures
Figure 1. Radioimmunotherapy Product Picture
Figure 2. Global Radioimmunotherapy Market Share by Type: 2024 VS 2031
Figure 3. Beta-emitting Features
Figure 4. Targeted Alpha Therapy Features
Figure 5. Global Radioimmunotherapy Market Share by Application: 2024 VS 2031
Figure 6. Solid Tumor
Figure 7. Non Hodgkin Lymphoma
Figure 8. Radioimmunotherapy Report Years Considered
Figure 9. Global Radioimmunotherapy Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 10. Global Radioimmunotherapy Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Radioimmunotherapy Revenue Market Share by Region: 2020 VS 2024
Figure 12. North America Radioimmunotherapy Revenue (US$ Million) Growth Rate (2020-2031)
Figure 13. Europe Radioimmunotherapy Revenue (US$ Million) Growth Rate (2020-2031)
Figure 14. China Radioimmunotherapy Revenue (US$ Million) Growth Rate (2020-2031)
Figure 15. Latin America Radioimmunotherapy Revenue (US$ Million) Growth Rate (2020-2031)
Figure 16. Middle East & Africa Radioimmunotherapy Revenue (US$ Million) Growth Rate (2020-2031)
Figure 17. Global Radioimmunotherapy Market Share by Players in 2024
Figure 18. Global Top Radioimmunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radioimmunotherapy as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Radioimmunotherapy Revenue in 2024
Figure 20. North America Radioimmunotherapy Market Share by Type (2020-2025)
Figure 21. North America Radioimmunotherapy Market Share by Application (2020-2025)
Figure 22. Europe Radioimmunotherapy Market Share by Type (2020-2025)
Figure 23. Europe Radioimmunotherapy Market Share by Application (2020-2025)
Figure 24. China Radioimmunotherapy Market Share by Type (2020-2025)
Figure 25. China Radioimmunotherapy Market Share by Application (2020-2025)
Figure 26. Latin America Radioimmunotherapy Market Share by Type (2020-2025)
Figure 27. Latin America Radioimmunotherapy Market Share by Application (2020-2025)
Figure 28. Middle East & Africa Radioimmunotherapy Market Share by Type (2020-2025)
Figure 29. Middle East & Africa Radioimmunotherapy Market Share by Application (2020-2025)
Figure 30. Bayer Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 31. Novartis Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 32. Lantheus Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 33. Aurobindo Pharma Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 34. Mundipharma Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 35. China Isotope & Radiation Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 36. Curium Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 37. Gilead Sciences Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 38. Clarity Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 39. Curasight Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 40. Nordic Nanovector Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 41. Philogen Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 42. RadioMedix Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 43. Telix Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 44. Orano Med Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 45. Actinium Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 46. Y-mAbs Therapeutics Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 47. Fusion Pharmaceuticals Revenue Growth Rate in Radioimmunotherapy Business (2020-2025)
Figure 48. Bottom-up and Top-down Approaches for This Report
Figure 49. Data Triangulation
Figure 50. Key Executives Interviewed